-1%

Cyramza 500mg/50ml

Original price was: $5,999.00.Current price is: $5,924.72.

United States dollar ($) - USD
  • United States dollar ($) - USD
  • Indian rupee (₹) - INR
  • Euro (€) - EUR
  • Australian dollar ($) - AUD
  • Pound sterling (£) - GBP
  • Japanese yen (¥) - JPY

Content: Ramucirumab 500mg
MAC: Lilly

Category:

Description

Description: Cyramza (ramucirumab) is a monoclonal antibody that acts as a vascular endothelial growth factor receptor 2 (VEGFR2) antagonist, used in the treatment of various cancers.

Contents: Each 50ml vial contains 500mg of ramucirumab.

Uses:

  • Gastric Cancer: As a single agent or in combination with paclitaxel for advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma after prior chemotherapy.
  • Non-Small Cell Lung Cancer (NSCLC): In combination with erlotinib for first-line treatment of metastatic NSCLC with specific genetic mutations, or with docetaxel for patients with disease progression after platinum-based chemotherapy.
  • Colorectal Cancer: In combination with FOLFIRI for metastatic colorectal cancer after prior therapy.
  • Hepatocellular Carcinoma: As a single agent for patients with hepatocellular carcinoma who have an alpha-fetoprotein level of ≥400 ng/mL.

How it Works: Ramucirumab binds to VEGFR2, inhibiting the interaction between VEGF and its receptor, which reduces blood supply to tumors and slows their growth.

Directions for Use: Administered via intravenous infusion. The recommended dose is typically 8 mg/kg every 2 weeks. Infusion should be performed over 60 minutes, and it should not be given as an intravenous push or bolus.

Side Effects:

  • Common side effects include hypertension, fatigue, diarrhea, nausea, and decreased appetite.
  • Serious side effects may include severe bleeding, gastrointestinal perforations, and arterial thromboembolic events.

Precautions:

  • Monitor blood pressure regularly; manage hypertension before treatment.
  • Discontinue use if severe bleeding occurs.
  • Not recommended during pregnancy or breastfeeding due to potential harm to the fetus or infant.
  • Patients should use effective contraception during treatment and for at least three months afterward due to potential effects on fertility.